Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Aly M Abdelrahman, Alaa S Awad, Irtiza Hasan, Emaad M Abdel-Rahman, Alberto Martínez-Castelao · 2024
Read Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side by Aly M Abdelrahman, Alaa S Awad, Irtiza Hasan, Emaad M Abdel-Rahman, Alberto Martínez-Castelao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677827.txt.
Description
Aly Abdelrahman and co-authors review a class of diabetes drugs and how they may protect the kidneys. Their 2024 review covers GLP-1 receptor agonists, drugs now in wide use for type 2 diabetes. Kidney damage is a common and serious outcome of the disease, and these drugs seem to help the kidneys through several routes at once.
The authors walk through the ways the drugs may shield the kidneys, drawing on both animal work and human studies. They then gather what trials show about kidney outcomes in patients who take them. Safety in people with diabetes is covered as well. The review aims to give clinicians a bench-to-bedside picture of this drug class.
Catalog record
| CREATOR | Aly M Abdelrahman, Alaa S Awad, Irtiza Hasan, Emaad M Abdel-Rahman, Alberto Martínez-Castelao |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |